131 related articles for article (PubMed ID: 20167489)
1. The development of benzimidazoles as selective rho kinase inhibitors.
Sessions EH; Smolinski M; Wang B; Frackowiak B; Chowdhury S; Yin Y; Chen YT; Ruiz C; Lin L; Pocas J; Schröter T; Cameron MD; LoGrasso P; Feng Y; Bannister TD
Bioorg Med Chem Lett; 2010 Mar; 20(6):1939-43. PubMed ID: 20167489
[TBL] [Abstract][Full Text] [Related]
2. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
[TBL] [Abstract][Full Text] [Related]
4. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
[TBL] [Abstract][Full Text] [Related]
5. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
[TBL] [Abstract][Full Text] [Related]
6. Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.
Morwick T; Büttner FH; Cywin CL; Dahmann G; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Mao W; Marshall D; Paw Z; Shih CK; Wu F; Young E
J Med Chem; 2010 Jan; 53(2):759-77. PubMed ID: 20000469
[TBL] [Abstract][Full Text] [Related]
7. Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases.
Enkvist E; Kriisa M; Roben M; Kadak G; Raidaru G; Uri A
Bioorg Med Chem Lett; 2009 Nov; 19(21):6098-101. PubMed ID: 19800227
[TBL] [Abstract][Full Text] [Related]
8. High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK.
Vaasa A; Viil I; Enkvist E; Viht K; Raidaru G; Lavogina D; Uri A
Anal Biochem; 2009 Feb; 385(1):85-93. PubMed ID: 19017524
[TBL] [Abstract][Full Text] [Related]
9. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors.
Gong LL; Fang LH; Peng JH; Liu AL; Du GH
J Biotechnol; 2010 Feb; 145(3):295-303. PubMed ID: 19963024
[TBL] [Abstract][Full Text] [Related]
10. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
[TBL] [Abstract][Full Text] [Related]
11. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
[TBL] [Abstract][Full Text] [Related]
12. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
13. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
14. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Stavenger RA; Cui H; Dowdell SE; Franz RG; Gaitanopoulos DE; Goodman KB; Hilfiker MA; Ivy RL; Leber JD; Marino JP; Oh HJ; Viet AQ; Xu W; Ye G; Zhang D; Zhao Y; Jolivette LJ; Head MS; Semus SF; Elkins PA; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Doe CP; Bentley R; Chen ZX; Hu E; Lee D
J Med Chem; 2007 Jan; 50(1):2-5. PubMed ID: 17201404
[TBL] [Abstract][Full Text] [Related]
15. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
Cee VJ; Cheng AC; Romero K; Bellon S; Mohr C; Whittington DA; Bak A; Bready J; Caenepeel S; Coxon A; Deak HL; Fretland J; Gu Y; Hodous BL; Huang X; Kim JL; Lin J; Long AM; Nguyen H; Olivieri PR; Patel VF; Wang L; Zhou Y; Hughes P; Geuns-Meyer S
Bioorg Med Chem Lett; 2009 Jan; 19(2):424-7. PubMed ID: 19062275
[TBL] [Abstract][Full Text] [Related]
16. Chroman-3-amides as potent Rho kinase inhibitors.
Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
[TBL] [Abstract][Full Text] [Related]
17. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors.
Akama T; Dong C; Virtucio C; Sullivan D; Zhou Y; Zhang YK; Rock F; Freund Y; Liu L; Bu W; Wu A; Fan XQ; Jarnagin K
J Pharmacol Exp Ther; 2013 Dec; 347(3):615-25. PubMed ID: 24049062
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
Letellier MA; Guillard J; Caignard DH; Ferry G; Boutin JA; Viaud-Massuard MC
Eur J Med Chem; 2008 Aug; 43(8):1730-6. PubMed ID: 18164518
[TBL] [Abstract][Full Text] [Related]
20. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
